In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...

(AP Photo/Amanda Andrade-Rhoades, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Makers of the ...

Late-breaking results from Eli Lilly ... apnea and obesity improve their sleep disorder. It should be used with a reduced-calorie diet and increased physical activity. Eli Lilly and Company ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...